| Revenue growth | FY26 revenue declined 8% YoY to Rs 1,713 Cr. |
|---|---|
| Margins | Q4 EBITDA margin improved to 20.3% from 16.8% QoQ. |
| Order book | Improved order inflow uptick in crop protection segment. |
| Demand visibility | Improving customer demand and volume traction in Crop Protection. |
| Management confidence | Confident foundation in place for a stronger FY27. |
Growth
Q4 revenue grew 5% QoQ but declined 6% YoY. Pharmaceutical revenue grew 60% in H2 vs H1 FY26.
Outlook
Expects Specialty Chemicals contribution from FY27. DMF filings target increased to 5-6 annually. US FDA CAPAs nearing completion.
Risks
Exceptional impairment costs at Panoli and new labor code impact. Competitive pricing pressures in Crop Protection.
Earnings Call filed with NSE, NSE: HIKAL. Summary written with AI assistance from the document.
Hikal Ltd: key numbers
- Share price
- ₹217.58
- Market cap
- ₹2,683 Cr
- Revenue (annual)
- ₹1,713 Cr
- Net profit (annual)
- ₹-48.80 Cr
- P/E (TTM)
- -79.4×Sector 50.4×
- Promoter holding
- 68.85%+0.00% QoQ
- FII holding
- 0.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hikal Ltd
All →Hikal Annual General Meeting
Hikal Ltd held its 38th AGM on September 23, 2026, approving financial statements, director appointments, remuneration revisions, and declaring a total dividend of ₹0.60 per share.
Hikal Production Started
Hikal has begun commercial production at its new cGMP Panoli facility, entering Personal Care manufacturing. First batches of UV filters and skincare ingredients are now being supplied to global customers.
Hikal Earnings Call Transcript: Key Takeaways
Hikal reported Q1 FY27 revenue of Rs 403 Cr with 9.2% EBITDA margin. Results show recovery post-regulatory disruption, driven by Pharma and Animal Health scaling.
- Call
- Guides 15% growth
Hikal Investor Presentation: Key Takeaways
Hikal reported Q1FY27 revenue of ₹403 Cr, up 6% YoY. Focus remains on pharma remediation and commissioning the Panoli facility for Personal Care.
Hikal Q1 FY27 Results: Net Loss of ₹7.4 Cr, Loss Narrows
Hikal Ltd reported revenue from operations of ₹402.8 Cr (+5.9% YoY) and a net loss of ₹7.4 Cr for Q1 FY27.
- Key figure
- Net loss ₹7.4 Cr
Hikal Earnings Call: Key Takeaways
Q4FY26 revenue hit ₹519cr with 20.3% EBITDA margin. Management focuses on transition from remediation to sustainable technology-led growth despite US FDA and raw material headwinds.